Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 1952-1963

  Winkler, Thomas ^a   Hong, So Gun ^a   Decker, Jake E ^a,b   Morgan, Mary J ^a   Wu, Chuanfeng ^a   William, M ^a   Hughes, V ^a   Yang, Yanqin ^a   Wangsa, Danny ^c   Padilla Nash, Hesed M ^c   Ried, Thomas ^c   Young, Neal S ^a   Dunbar, Cynthia E ^a   Calado, Rodrigo T ^a,d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL ELONGATION; CELL HETEROGENEITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; GENE EXPRESSION REGULATION; GENE MUTATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; TELOMERE; TELOMERE HOMEOSTASIS;

ANEMIA, APLASTIC; ANIMALS; CELL DIFFERENTIATION; DNA MUTATIONAL ANALYSIS; ENVIRONMENT; FIBROBLASTS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INDUCED PLURIPOTENT STEM CELLS; LEUKOCYTES; MICE; MUTATION; PHENOTYPE; TELOMERASE; TELOMERE; TRANSGENES;

EID: 84877105959     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67146     Document Type: Article

References (51)

1. de Lange T. How telomeres solve the end-protection problem. Science. 2009;326(5955):948-952.
2. Venteicher AS, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 2009; 323(5914):644-648.
3. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-2365.
4. Kirwan M, Dokal I. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta. 2009; 1792(4):371-379.
5. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009;23(2):215-231.
6. Yamaguchi H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352(14):1413-1424.
7. Armanios MY, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356(13):1317-1326.
8. Tsakiri KD, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007;104(18):7552-7557.
9. Calado RT, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology. 2011;53(5):1600-1607.
10. Calado RT, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One. 2009;4(11):e7926.
11. Hartmann D, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology. 2011;53(5):1608-1617.
12. Calado RT, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A. 2009; 106(4):1187-1192.
13. Kirwan M, et al. Dyskeratosis congenita and the DNA damage response. Br J Haematol. 2011; 153(5):634-643.
14. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
15. Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391):1145-1147.
16. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.
17. Maherali N, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007; 1(1):55-70.
18. Marion RM, et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell. 2009;4(2):141-154.
19. Yehezkel S, et al. Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives. Epigenetics. 2011;6(1):63-75.
20. Agarwal S, et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature. 2010;464(7286):292-296.
21. Batista LF, et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature. 2011; 474(7351):399-402.
22. Ezashi T, Das P, Roberts RM. Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci U S A. 2005;102(13):4783-4788.
23. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009; 5(3):237-241.
24. El-Chemaly S, et al. Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation. Chest. 2011;139(5):1203-1209.
25. Aalbers AM, Kajigaya S, van den Heuvel-Eibrink MM, van der Velden VH, Calado RT, Young NS. Human telomere disease due to disruption of the CCAAT box of the TERC promoter. Blood. 2012;119(13):3060-3063.
26. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. Generation of human-induced pluripotent stem cells. Nat Protoc. 2008;3(7):1180-1186.
27. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells. 2009; 27(3):543-549.
28. Schrock E, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996; 273(5274):494-497.
29. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
30. Hoffmeyer K, et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012;336(6088):1549-1554.
31. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010;11(5):319-330.
32. Henson JD, et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol. 2009; 27(12):1181-1185.
33. Allen ND, Baird DM. Telomere length maintenance in stem cell populations. Biochim Biophys Acta. 2009; 1792(4):324-328.
34. Wu KJ, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999;21(2):220-224.
35. Chang YF, Imam JS, Wilkinson MF. The nonsensemediated decay RNA surveillance pathway. Annu Rev Biochem. 2007;76:51-74.
36. Dokal I. Dyskeratosis congenita. A disease of premature ageing. Lancet. 2001;358:S27.
37. Diaz de Leon A, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5(5):e10680.
38. Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36(5):447-449.
39. Chiang YJ, Calado RT, Hathcock KS, Lansdorp PM, Young NS, Hodes RJ. Telomere length is inherited with resetting of the telomere set-point. Proc Natl Acad Sci U S A. 2010;107(22):10148-10153.
40. Armanios M, Alder JK, Parry EM, Karim B, Strong MA, Greider CW. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet. 2009;85(6):823-832.
41. Martins-Taylor K, Xu RH. Concise review: Genomic stability of human induced pluripotent stem cells. Stem Cells. 2012;30(1):22-27.
42. Coussens M, et al. RNAi screen for telomerase reverse transcriptase transcriptional regulators identifies HIF1alpha as critical for telomerase function in murine embryonic stem cells. Proc Natl Acad Sci U S A. 2010;107(31):13842-13847.
43. von Zglinicki T, Pilger R, Sitte N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med. 2000;28(1):64-74.
44. Agarwal S, Daley GQ. Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Cell Res. 2011;21(8):1157-1160.
45. Calado RT, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114(11):2236-2243.
46. Huangfu D, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008; 26(7):795-797.
47. Chadwick K, et al. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood. 2003;102(3):906-915.
48. Scaffer LG, Slovak ML, Campbell LJ, eds. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger Publishing; 2009.
49. Sommer CA, et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells. 2010;28(1):64-74.
50. Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 2009;37(3):e21.
51. Henson JD, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005; 11(1):217-225.